Complix
ActiveSummary
Complix has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€281,978) and a net result of -€139,447. Equity is shrinking by ~63.8% per year across the filed fiscal years. Its solvency ranks better than 9% of 216 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability0=
Solvency0=
Growth58▼-20
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity ample (current ratio 2.23 against 2.59 in 2024; short-term debt: 20% and cash: 30.5% of total assets), but equity is negative.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-135.6%
Return on assets
-67.1%
Age of the figures
9 mo
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€281,978
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-05-2026, 65 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
65 d early
2024
87 d early
2023
79 d early
2022
72 d early
2021
31 d early
2020
58 d early
2019
29 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 60 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
27-09-2026 today31-12-2026 close31-07-2027 deadline
History
On 1 July 2008, Complix was incorporated.1 In 2010 the registered office moved to Diepenbeek.2 The capital was increased 11 times between 2010 and 2022, most recently to EUR 2.9 million.234 Of the 2 current board members, LRM Beheer has served longest, since 2013.4 Total assets went from EUR 1.1 million in 2018 to EUR 207,946 in 2025 and headcount from 17 full-time equivalents in 2018 to 12.9 in 2022.5
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money How does this company compare with its sector?Sector benchmark
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Equity
-€281,978▼ 97.8%
2024 · -€142,532
Total assets
€207,946▼ 32.7%
2024 · €308,918
Net result
-€139,447▼ 7.1%
2024 · -€130,203
Working capital
€50,998▼ 54.3%
2024 · €111,559
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result-€2.0m▼ 4.9%-€1.0m▲ 49.3%-€133,649▲ 86.7%-€128,690▲ 3.7%-€135,700▼ 5.4%
Net result-€2.0mbelow the sector's middle half▼ 14.6%-€1.0mbelow the sector's middle half▲ 49.0%-€138,505below the sector's middle half▲ 86.3%-€130,203below the sector's middle half▲ 6.0%-€139,447within the sector's middle half▼ 7.1%
Equity€333,587within the sector's middle half▼ 47.0%€126,177below the sector's middle half▼ 62.2%-€12,329below the sector's middle half-€142,532below the sector's middle half▼ 1,056%-€281,978below the sector's middle half▼ 97.8%
Total assets€902,283within the sector's middle half▼ 30.4%€536,427below the sector's middle half▼ 40.5%€381,366below the sector's middle half▼ 28.9%€308,918below the sector's middle half▼ 19.0%€207,946below the sector's middle half▼ 32.7%
Debt€568,697▼ 14.7%€410,250▼ 27.9%€393,695▼ 4.0%€451,449▲ 14.7%€489,924▲ 8.5%
Working capital€134,489▼ 80.5%€356,532▲ 165%€222,513▼ 37.6%€111,559▼ 49.9%€50,998▼ 54.3%
Solvency37.0%within the sector's middle half▼ 11.6pp23.5%within the sector's middle half▼ 13.4pp-3.2%below the sector's middle half▼ 26.8pp-46.1%below the sector's middle half▼ 42.9pp-135.6%below the sector's middle half▼ 89.5pp
Staff (FTE)16.3within the sector's middle half▲ 32.5%12.9within the sector's middle half▼ 20.9%
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Why a figure moved sharply
- 2022 Equity -62% on 2021. Capital reduction of €1,870,824 (Official Gazette 16-06-2022).
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €135,700 in 2025 against €128,690 in 2024; the loss grows.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €207,946
Fixed assets
€115,346 ▼ 9.2%
Current assets
€92,600 ▼ 49.1%
Key figures and ratios
EBITDA
-€87,275▼
2024 · -€82,708
Cash flow
-€91,021▼
2024 · -€84,221
Current ratio
2.23▼
2024 · 2.59
Debt to equity
-1.74▲
2024 · -3.17
ROA
-67.1%▼
2024 · -42.1%
Interest coverage
-28.46▼
2024 · -27.38
Debt ≤ 1 year
€41,601▼
2024 · €70,354
Debt > 1 year
€439,679▲
2024 · €374,679
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 6,943 companies that looked in July 2024 the way this one looks now, 5.5% went bankrupt within 24 months and 85% are still going.
- Micro
- 10 to 20 years old
- negative equity
- a loss of 10% of the balance sheet or more
5.5%
went bankrupt
8.1%
stopped otherwise
85%
still going
A further 1.5% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.5% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.6% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 6,943 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | €4,500 | €203,145 | - | - | - | - |
| Remuneration, social security and pensions62 | €1.2m | €643,388 | €585 | €1,191 | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €84,467 | €43,663 | €40,334 | €45,982 | €48,425 | ▲ 5.3% |
| Other operating charges640/8 | €2,371 | €9,969 | €588 | €1,586 | €2,536 | ▲ 60.0% |
| Gross operating margin9900 | -€738,273 | -€309,412 | -€92,142 | -€79,931 | -€84,739 | ▼ 6.0% |
| Operating profit (loss)9901 | -€2.0m | -€1.0m | -€133,649 | -€128,690 | -€135,700 | ▼ 5.4% |
| Financial income75/76B | €20,202 | €2,837 | €324 | €2,702 | €913 | ▼ 66.2% |
| Recurring financial income75 | €20,202 | €2,837 | €324 | €2,702 | €913 | ▼ 66.2% |
| Financial charges65/66B | €13,895 | €4,059 | €5,180 | €3,020 | €4,659 | ▲ 54.3% |
| Recurring financial charges65 | €13,895 | €4,059 | €5,180 | €3,020 | €3,066 | ▲ 1.5% |
| Non-recurring financial charges66B | - | - | - | - | €1,593 | - |
| Profit (loss) for the period before taxes9903 | -€2.0m | -€1.0m | -€138,505 | -€129,009 | -€139,447 | ▼ 8.1% |
| Income taxes67/77 | €863 | €223 | - | €1,194 | - | - |
| Profit (loss) for the period9904 | -€2.0m | -€1.0m | -€138,505 | -€130,203 | -€139,447 | ▼ 7.1% |
| Profit (loss) for the period to be appropriated9905 | -€2.0m | -€1.0m | -€138,505 | -€130,203 | -€139,447 | ▼ 7.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €902,283 | €536,427 | €381,366 | €308,918 | €207,946 | ▼ 32.7% |
| Fixed assets21/28 | €245,176 | €143,653 | €145,570 | €127,004 | €115,346 | ▼ 9.2% |
| Intangible fixed assets21 | €124,537 | €126,773 | €128,690 | €110,123 | €98,466 | ▼ 10.6% |
| Tangible fixed assets22/27 | €103,758 | - | - | - | - | - |
| Plant, machinery and equipment23 | €96,099 | - | - | - | - | - |
| Furniture and vehicles24 | €7,660 | - | - | - | - | - |
| Financial fixed assets28 | €16,880 | €16,880 | €16,880 | €16,880 | €16,880 | = |
| Current assets29/58 | €657,108 | €392,774 | €235,796 | €181,914 | €92,600 | ▼ 49.1% |
| Stocks and contracts in progress3 | €32,086 | - | - | - | - | - |
| Stocks30/36 | €32,086 | - | - | - | - | - |
| Amounts receivable within one year40/41 | €86,514 | €26,736 | €16,872 | €65,575 | €28,552 | ▼ 56.5% |
| Trade receivables40 | €2,312 | €3,922 | - | €57,176 | €14,049 | ▼ 75.4% |
| Other amounts receivable41 | €84,202 | €22,814 | €16,872 | €8,399 | €14,504 | ▲ 72.7% |
| Current investments50/53 | - | - | €160,000 | - | - | - |
| Cash at bank and in hand54/58 | €518,863 | €355,145 | €51,271 | €110,052 | €63,523 | ▼ 42.3% |
| Deferred charges and accrued income490/1 | €19,645 | €10,893 | €7,653 | €6,287 | €525 | ▼ 91.7% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €902,283 | €536,427 | €381,366 | €308,918 | €207,946 | ▼ 32.7% |
| Equity10/15 | €333,587 | €126,177 | -€12,329 | -€142,532 | -€281,978 | ▼ 97.8% |
| Contributions10/11 | €2.1m | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Capital10 | €2.1m | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Issued capital100 | €2.1m | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Profit (loss) carried forward14 | -€1.8m | -€904,780 | -€1.0m | -€1.2m | -€1.3m | ▼ 11.9% |
| Amounts payable17/49 | €568,697 | €410,250 | €393,695 | €451,449 | €489,924 | ▲ 8.5% |
| Amounts payable after more than one year17 | - | €370,929 | €373,929 | €374,679 | €439,679 | ▲ 17.3% |
| Financial debts170/4 | - | €370,929 | €373,929 | €374,679 | €439,679 | ▲ 17.3% |
| Amounts payable within one year42/48 | €522,618 | €36,242 | €13,283 | €70,354 | €41,601 | ▼ 40.9% |
| Financial debts43 | €14 | - | - | - | - | - |
| Credit institutions430/8 | €14 | - | - | - | - | - |
| Trade debts44 | €345,036 | €35,884 | €13,283 | €70,354 | €39,999 | ▼ 43.1% |
| Suppliers440/4 | €345,036 | €35,884 | €13,283 | €70,354 | €39,999 | ▼ 43.1% |
| Taxes, remuneration and social security45 | €177,568 | €358 | - | - | €1,602 | - |
| Taxes450/3 | - | €358 | - | - | €1,602 | - |
| Remuneration and social security454/9 | €177,568 | - | - | - | - | - |
| Accrued charges and deferred income492/3 | €46,078 | €3,079 | €6,483 | €6,416 | €8,644 | ▲ 34.7% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€2.0m | -€1.0m | -€138,505 | -€130,203 | -€139,447 | ▼ 7.1% |
| + Depreciation and write-downs630 | €84,467 | €43,663 | €40,334 | €45,982 | €48,425 | ▲ 5.3% |
| Operating cash flow (approximation) | -€1.9m | -€964,213 | -€98,171 | -€84,221 | -€91,021 | ▼ 8.1% |
| Investment in fixed assets (approximation) | - | €57,859 | -€42,251 | -€27,416 | -€36,768 | ▼ 34.1% |
| Change in cash | - | -€163,718 | -€303,874 | €58,781 | -€46,529 | ▼ 179% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
10-02
State Gazette act
Resignation: Johan Cardoen (director)Permanent representative: Mark Vaeck · Appointment: Mavelki BV (director) · No officer appointment4 facts ▸
State Gazette act
Resignation: Johan Cardoen (director)
Permanent representative: Mark Vaeck · Appointment: Mavelki BV (director) · No officer appointment4 facts ▸
- Director resignation, Johan Cardoen (director)
- Permanent representative, Mark Vaeck
- Director appointment, Mavelki BV (director)
- No officer appointment, bestuurder
2025
05-05
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
30-05
State Gazette act
Resignation: Johannes Schikan (director)2 facts ▸
State Gazette act
Resignation: Johannes Schikan (director)
2 facts ▸
- Board meeting, 27-03-2024
- Director resignation, Johannes Schikan (director)
13-05
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
10-10
State Gazette act
Reappointment: Mavelki BV (managing director)Permanent representative: Mark Vaeck3 facts ▸
State Gazette act
Reappointment: Mavelki BV (managing director)
Permanent representative: Mark Vaeck3 facts ▸
- Board meeting, 25-08-2023
- Director reappointment, Mavelki BV (managing director)
- Permanent representative, Mark Vaeck
20-05
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Liquidity times 9current ratio 10.84
Current ratio from 1.26 to 10.84; short-term debt falls from €522,618 to €36,242.
30-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
16-06
State Gazette act
Resignations: Thierry Hercend (independent director) and Johan Cardoen (director)Appointments: LRM Beheer NV (director) and Johan Cardoen (independent director) · Permanent representative: Tom Aerts · Capital increase15 facts ▸
State Gazette act
Resignations: Thierry Hercend (independent director) and Johan Cardoen (director)
Appointments: LRM Beheer NV (director) and Johan Cardoen (independent director) · Permanent representative: Tom Aerts · Capital increase15 facts ▸
- General meeting, 09-05-2022
- Capital increase, €800.465,85
- Capital decrease, €1.870.823,95
- Share cancellation, niet-toegekende inschrijvingsrechten, 81935517
- Statutes amendment
- Capital, €1.030.956,92
- Director resignation, Thierry Hercend (independent director)
- Director resignation, Johan Cardoen (director)
- Director appointment, LRM Beheer NV (director)
- Director appointment, Johan Cardoen (independent director)
- Permanent representative, Tom Aerts
- Mandate compensation, LRM Beheer NV
- +3 further facts in this act
2021
31-12
Financial
Weakest financial yearnet -€2.0m
Net result drops to -€2.0m, the lowest in the series; recovery starts the following year.
03-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
Show earlier events
30-04
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Capital decrease · Share cancellation7 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Capital decrease · Share cancellation7 facts ▸
- General meeting, 14-04-2021
- Capital increase, €1.681.494,29
- Capital decrease, €1.649.586,16
- Share cancellation, inschrijvingsrechten, 15868535
- Share issue, Inschrijvingsrechten, 81935517
- Statutes amendment, Artikel 5
- Capital, €2.101.315,02
2020
15-12
State Gazette act
Resignation: LRM Beheer NV (director)Appointment: Johan Cardoen (non-executive director) · Director discharge · Mandate compensation5 facts ▸
State Gazette act
Resignation: LRM Beheer NV (director)
Appointment: Johan Cardoen (non-executive director) · Director discharge · Mandate compensation5 facts ▸
- General meeting, 20-11-2020
- Director resignation, LRM Beheer NV (director)
- Director discharge, LRM Beheer NV
- Director appointment, Johan Cardoen (non-executive director)
- Mandate compensation, Johan Cardoen
02-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
29-06
State Gazette act
Resignations: Yvonne McGrath, Patrick Van Beneden and Gilles NobecourtCapital increase · Capital decrease · Share cancellation10 facts ▸
State Gazette act
Resignations: Yvonne McGrath, Patrick Van Beneden and Gilles Nobecourt
Capital increase · Capital decrease · Share cancellation10 facts ▸
- General meeting, 26-05-2020
- Capital increase, €1.717.945,77
- Capital decrease, €29.565.456,27
- Share cancellation, Investeerders Warrants en Klasse D Anti-Dilutie Warrants
- Share issue, winstbewijzen, 3252809
- Statutes amendment
- Capital, €2.069.406,89
- Director resignation, Yvonne McGrath (director)
- Director resignation, Patrick Van Beneden (director)
- Director resignation, Gilles Nobecourt (director)
18-03
State Gazette act
Resignation: Katleen Vandersmissen (permanent representative)Permanent representative: Tom Aerts · Power of attorney4 facts ▸
State Gazette act
Resignation: Katleen Vandersmissen (permanent representative)
Permanent representative: Tom Aerts · Power of attorney4 facts ▸
- Board meeting, 09-01-2020
- Director resignation, Katleen Vandersmissen (permanent representative)
- Permanent representative, Tom Aerts (permanent representative)
- Power of attorney, Deloitte Legal Lawyers
2019
31-12
Financial
Equity above €500,000Eq €638,257
Equity rises from -€175,471 to €638,257.
14-08
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Bank account · Capital6 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Bank account · Capital6 facts ▸
- General meeting, 24-07-2019
- Capital increase, €295.701,62
- Bank account, bijzondere rekening geopend op naam van de vennootschap bij BNP Paribas Fortis NV
- Capital, €29.916.917,39
- Share issue, Klasse D Anti-dilutie Warrants, 110
- Share issue, stock optie warrants
19-07
State Gazette act
Resignation: Véronique Vermeeren (permanent representative)Appointment: Katleen Vandersmissen (permanent representative) · Reappointments: BDO Bedrijfsrevisoren, Mavelki BVBA and 7 others · Mandate compensation14 facts ▸
State Gazette act
Resignation: Véronique Vermeeren (permanent representative)
Appointment: Katleen Vandersmissen (permanent representative) · Reappointments: BDO Bedrijfsrevisoren, Mavelki BVBA and 7 others · Mandate compensation14 facts ▸
- Board meeting, 05-06-2019
- Director resignation, Véronique Vermeeren (permanent representative)
- Director appointment, Katleen Vandersmissen (permanent representative)
- General meeting, 25-06-2019
- Auditor reappointment, BDO Bedrijfsrevisoren
- Director reappointment, Mavelki BVBA (director)
- Director reappointment, Vesalius Biocapital Partners SARL (director)
- Director reappointment, LRM Beheer (director)
- Director reappointment, Patrick Van Beneden (director)
- Director reappointment, Andera Partners (director)
- Director reappointment, Johannes Schikan (director)
- Director reappointment, Thierry Hercend (director)
- +2 further facts in this act
17-07
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Capital · Share cancellation6 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Capital · Share cancellation6 facts ▸
- General meeting, 14-06-2019
- Capital increase, €1.400.000
- Capital, €29.621.215,77
- Statutes amendment
- Share cancellation, Bestaande Klasse C Anti-dilutie Warrants
- Share issue, Klasse D Anti-dilutie Warrants, 70
27-06
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
09-05
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
28-07
State Gazette act
Resignation: Barbara Leyman (permanent representative)Appointment: Véronique Vermeeren (permanent representative) · Capital increase · Capital16 facts ▸
State Gazette act
Resignation: Barbara Leyman (permanent representative)
Appointment: Véronique Vermeeren (permanent representative) · Capital increase · Capital16 facts ▸
- General meeting, 30-06-2017
- Capital increase, €404.063,4
- Capital increase, €4.504.755,73
- Capital increase, €2.000.000
- Capital, €28.221.215,77
- Statutes amendment
- Share cancellation, Klasse A Anti-dilutie Warrants, bestaande
- Share cancellation, Klasse B Anti-dilutie Warrants, bestaande
- Share cancellation, Stock Optie Warrants, 278004
- Share cancellation, Stock Optie Warrants, 456651
- Share issue, Klasse C Anti-dilutie Warrants, 340
- Share issue, Investeerder Warrants, 3817765
- +4 further facts in this act
22-05
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
2016
16-12
State Gazette act
Permanent representative: Thomas Durieux1 fact ▸
State Gazette act
Permanent representative: Thomas Durieux
1 fact ▸
- Permanent representative, Thomas Durieux
24-06
State Gazette act
Reappointment: BDO Bedrijfsrevisoren (statutory auditor)2 facts ▸
State Gazette act
Reappointment: BDO Bedrijfsrevisoren (statutory auditor)
2 facts ▸
- General meeting, 26-04-2016
- Auditor reappointment, BDO Bedrijfsrevisoren
17-06
State Gazette act
Capital & sharesBond issue2 facts ▸
State Gazette act
Capital & shares
Bond issue2 facts ▸
- General meeting, 26-05-2016
- Bond issue, 447964, EUR
09-02
State Gazette act
Resignation: Omnes Capital SA (director)Bond issue · Statutes amendment4 facts ▸
State Gazette act
Resignation: Omnes Capital SA (director)
Bond issue · Statutes amendment4 facts ▸
- General meeting, 20-01-2016
- Bond issue, 362996, 164147.12
- Statutes amendment
- Director resignation, Omnes Capital SA (director)
2015
15-12
State Gazette act
Permanent representatives: Barbara Leyman and Debora Dumont2 facts ▸
State Gazette act
Permanent representatives: Barbara Leyman and Debora Dumont
2 facts ▸
- Permanent representative, Barbara Leyman
- Permanent representative, Debora Dumont
09-11
State Gazette act
Appointment: Hans Schikan (director)Permanent representatives: Mark Vaeck, Gaston Matthyssens and 3 others · Mandate compensation17 facts ▸
State Gazette act
Appointment: Hans Schikan (director)
Permanent representatives: Mark Vaeck, Gaston Matthyssens and 3 others · Mandate compensation17 facts ▸
- General meeting, 20-07-2015
- Director appointment, Hans Schikan (director)
- Mandate compensation, Hans Schikan
- Board composition, Hans Schikan (director)
- Board composition, Mavelki bvba (director)
- Permanent representative, Mark Vaeck
- Board composition, Vesalius Biocapital Partners S.à.r.l. (director)
- Permanent representative, Gaston Matthyssens
- Board composition, Yvonne McGrath (director)
- Board composition, EdRIP (director)
- Permanent representative, Gilles Nobecourt
- Board composition, Thierry Hercend (director)
- +5 further facts in this act
10-04
State Gazette act
Capital & sharesCapital increase · Capital · Statutes amendment5 facts ▸
State Gazette act
Capital & shares
Capital increase · Capital · Statutes amendment5 facts ▸
- General meeting, 13-03-2015
- Capital increase, €2.839.907
- Capital increase, €27
- Capital, €21.312.396,64
- Statutes amendment
18-02
State Gazette act
Permanent representatives: Cédric Lecureuil and Bruno MontanariPower of attorney5 facts ▸
State Gazette act
Permanent representatives: Cédric Lecureuil and Bruno Montanari
Power of attorney5 facts ▸
- Board meeting, 04-09-2014
- Permanent representative, Cédric Lecureuil
- Permanent representative, Bruno Montanari
- Power of attorney, Christoph Michiels
- Power of attorney, Katti Van Oosterwijck
2014
27-05
State Gazette act
Appointment: Yvonne McGrath (director)Resignation: Beagle BVBA (director) · Permanent representative: Ignace Lasters · Capital increase10 facts ▸
State Gazette act
Appointment: Yvonne McGrath (director)
Resignation: Beagle BVBA (director) · Permanent representative: Ignace Lasters · Capital increase10 facts ▸
- General meeting, 29-04-2014
- Capital increase, €3.738.354
- Capital, €18.472.462,64
- Share cancellation, Stock Optiewarrants, 47000
- Share issue, stock optie warrants, 1908118
- Director appointment, Yvonne McGrath (director)
- Director resignation, Beagle BVBA
- Permanent representative, Ignace Lasters
- Mandate term, tot afloop van de gewone algemene vergadering van 2020
- Mandate compensation, Beagle BVBA
09-05
State Gazette act
Permanent representative: Cédric Lecureuil2 facts ▸
State Gazette act
Permanent representative: Cédric Lecureuil
2 facts ▸
- Board meeting, 05-02-2014
- Permanent representative, Cédric Lecureuil
2013
20-08
State Gazette act
Resignations: Mavelki BVBA, Beagle BVBA and 4 othersAppointments: Vesalius Biocapital Partners S.à.r.l., LRM Beheer NV and 6 others · Permanent representatives: Gaston Matthysens, Debora Dumont and 4 others · Capital increase30 facts ▸
State Gazette act
Resignations: Mavelki BVBA, Beagle BVBA and 4 others
Appointments: Vesalius Biocapital Partners S.à.r.l., LRM Beheer NV and 6 others · Permanent representatives: Gaston Matthysens, Debora Dumont and 4 others · Capital increase30 facts ▸
- General meeting, 27/06/2013
- Capital increase, €2.211.791
- Capital increase, €298.128
- Capital increase, €2.974.189
- Share issue, Klasse A Anti-dilutie Warrants, 160
- Share issue, Klasse B Anti-dilutie Warrants, 270
- Share issue, Prijsaanpassingswarrants, 27
- Statutes amendment
- Capital, €14.734.108,64
- Director resignation, Mavelki BVBA (director)
- Director resignation, Beagle BVBA (director)
- Director resignation, Omnes Capital S.A. (director)
- +18 further facts in this act
05-07
State Gazette act
Reappointment: BDO Bedrijfsrevisoren Burg. Ven. CVBA (statutory auditor)Permanent representative: Luc Annick3 facts ▸
State Gazette act
Reappointment: BDO Bedrijfsrevisoren Burg. Ven. CVBA (statutory auditor)
Permanent representative: Luc Annick3 facts ▸
- General meeting, 30-04-2013
- Auditor reappointment, BDO Bedrijfsrevisoren Burg. Ven. CVBA
- Permanent representative, Luc Annick
19-03
State Gazette act
MiscellaneousGeneral meeting1 fact ▸
State Gazette act
Miscellaneous
General meeting1 fact ▸
- General meeting, 20-02-2013
2012
22-11
State Gazette act
Resignations & appointmentsGeneral meeting1 fact ▸
State Gazette act
Resignations & appointments
General meeting1 fact ▸
- General meeting, 30-10-2012
2011
28-10
State Gazette act
Capital & sharesWarrant issue2 facts ▸
State Gazette act
Capital & shares
Warrant issue2 facts ▸
- General meeting, 29-06-2011
- Warrant issue, warrants, 719875
27-07
State Gazette act
Capital & sharesShare issue2 facts ▸
State Gazette act
Capital & shares
Share issue2 facts ▸
- General meeting, 29-06-2011
- Share issue, warrants
21-01
State Gazette act
Appointment: Crédit Agricole Private Equity S.A. (director)Permanent representative: Emmanuelle Coutanceau · Share issue · Capital increase7 facts ▸
State Gazette act
Appointment: Crédit Agricole Private Equity S.A. (director)
Permanent representative: Emmanuelle Coutanceau · Share issue · Capital increase7 facts ▸
- General meeting, 23-12-2010
- Share issue, 60, Klasse A Anti-dilutie Warrants
- Capital increase, €5.124.031,89
- Capital, €9.250.000,64
- Director appointment, Crédit Agricole Private Equity S.A. (director)
- Permanent representative, Emmanuelle Coutanceau
- Mandate compensation, Crédit Agricole Private Equity S.A.
2010
21-06
State Gazette act
Permanent representatives: Bart De Smet, Edwin Zimmermann and 4 othersResignations: TrustCapital, Koenraad Debackere and 3 others · Appointments: Vesalius Biocapital Partners, S.à.r.l., IMMOCOM and 4 others · Registered-office move26 facts ▸
State Gazette act
Permanent representatives: Bart De Smet, Edwin Zimmermann and 4 others
Resignations: TrustCapital, Koenraad Debackere and 3 others · Appointments: Vesalius Biocapital Partners, S.à.r.l., IMMOCOM and 4 others · Registered-office move26 facts ▸
- General meeting, 02-06-2010
- Registered-office move, 3590 Diepenbeek, Agoralaan, Gebouw Abis (zonder nummer)
- Capital increase, €1.875.968,75
- Capital, €4.125.968,75
- Permanent representative, Bart De Smet
- Permanent representative, Edwin Zimmermann
- Director resignation, TrustCapital (director)
- Director resignation, Koenraad Debackere (director)
- Director resignation, VINNOF (director)
- Director resignation, Mavelki BVBA (director)
- Director resignation, Beagle BVBA (director)
- Director appointment, Vesalius Biocapital Partners, S.à.r.l. (director)
- +14 further facts in this act
2008
31-12
State Gazette act
Resignation: BVBA Aquarius (director)Appointment: NV Trustcapital Delox (director) · Permanent representative: Patrick De Groote4 facts ▸
State Gazette act
Resignation: BVBA Aquarius (director)
Appointment: NV Trustcapital Delox (director) · Permanent representative: Patrick De Groote4 facts ▸
- Board meeting, 09-12-2008
- Director resignation, BVBA Aquarius (director)
- Director appointment, NV Trustcapital Delox (director)
- Permanent representative, Patrick De Groote
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
31 of 31 acts read
Directors · office · real estate
Directors
2 directors, 1 in day-to-day management, no change since 2026
Board 2
LRM Beheer
CurrentDirector · since 20-08-2013 · Public limited company · perm. rep.: Nico Vandervelpen
Mavelki BV
CurrentDirector · since 02-02-2026 · Legal entity · perm. rep.: Mark Vaeck
11 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
NV Trustcapital Delox
Not recently confirmedDirector · since 19-12-2008 · Legal entity · perm. rep.: Patrick De Groote
Crédit Agricole Private Equity S.A.
Not recently confirmedDirector · since 23-12-2010 · Legal entity · perm. rep.: Emmanuelle Coutanceau
BEAGLE
Not recently confirmedDirector · since 20-08-2013 · Private limited company · perm. rep.: Ignace Lasters
Edmond de Rothschild Investment Partners
Not recently confirmedDirector · since 20-08-2013 · Legal entity · perm. rep.: Gilles Nobecourt
Omnes Capital S.A.S.
Not recently confirmedDirector · since 20-08-2013 · Legal entity · perm. rep.: Emmanuelle Coutanceau
Vesalius Biocapital Partners S.à r.l
Not recently confirmedDirector · since 20-08-2013 · Legal entity · perm. rep.: Gaston Matthysens
Hans Schikan
Not recently confirmedDirector · since 01-07-2015
Andera Partners
Not recently confirmedDirector · Legal entity
LRM beheer
Not recently confirmedDirector · Legal entity
Mavelki BVBA
Not recently confirmedDirector · Legal entity · perm. rep.: Mark Vaeck
Vesalius Biocapital Partners SARL
Not recently confirmedDirector · Legal entity
Day-to-day management 1
Mavelki BV
CurrentManaging director · since 14-06-2022 · Legal entity · perm. rep.: Mark Vaeck
2 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Mavelki BVBA
Not recently confirmedDirector · since 02-06-2010 · Legal entity · perm. rep.: Mark Vaeck
MAVELKI
Not recently confirmedDirector · since 20-08-2013 · Private limited company · perm. rep.: Mark Vaeck
Permanent representatives 2
Nico Vandervelpen
CurrentPermanent representative · since 20-08-2013 · for LRM Beheer
Mark Vaeck
CurrentPermanent representative · since 02-02-2026 · for Mavelki BV
5 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Patrick De Groote
Not recently confirmedPermanent representative · since 19-12-2008 · for NV Trustcapital Delox
Emmanuelle Coutanceau
Not recently confirmedPermanent representative · since 20-08-2013 · for Omnes Capital S.A.S.
Gaston Matthysens
Not recently confirmedPermanent representative · since 20-08-2013 · for Vesalius Biocapital Partners S.à r.l
Gilles Nobecourt
Not recently confirmedPermanent representative · since 20-08-2013 · for Edmond de Rothschild Investment Partners
Ignace Lasters
Not recently confirmedPermanent representative · since 20-08-2013 · for BEAGLE
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Location & real-estate footprint
Registered office, Diepenbeek · 1 establishment unit since 2008
Ground area
7.9 ha
Building footprint
2.9 ha
2 parcels, Flanders. Linked by address, not a title deed.
11
companies at this address
See who is registered here
1 establishment unit
Complix
since 20082.231.762.736
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71011A0243/00W000 | Flanders | 5.4 ha | 1 · 2.9 ha | - |
| 71011A0272/00F000 | Flanders | 2.5 ha | - | - |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
31 people since 2008, 14 in office
- Board
- Day-to-day management
- Permanent representative
- Statutory auditor
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| LRM Beheer |
|
| Mavelki BV |
|
| NV Trustcapital Delox |
|
| Mavelki BVBA |
|
| Vesalius Biocapital Partners S.à r.l |
|
| Crédit Agricole Private Equity S.A. |
|
| BEAGLE |
|
| Edmond de Rothschild Investment Partners |
|
| Omnes Capital S.A.S. |
|
| Hans Schikan |
|
| Andera Partners |
|
| LRM beheer |
|
| Vesalius Biocapital Partners SARL |
|
| MAVELKI |
|
| CARDOEN Johan |
|
| Johannes Schikan |
|
| Thierry Hercend |
|
| LRM BEHEER NV |
|
| Gilles Nobecourt |
|
| Patrick Van Beneden |
|
| Yvonne McGrath |
|
| Katleen Vandersmissen |
|
| BDO Bedrijfsrevisoren |
|
| Véronique Vermeeren |
|
| Barbara Leyman |
|
| Omnes Capital SA |
|
| Beagle BVBA |
|
| Koenraad Debackere |
|
| TrustCapital |
|
| Vinnof |
|
| Aquarius BVBA |
|
Articles of association
Purpose
Moleculen, eiwitten of peptiden te ontwerpen, te ontwikkelen en te commercialiseren voor therapeutisch of diagnostisch gebruik
Structure & network
Owners and holdings
3 ownersOwners 3
-
30.08%
-
6.05%
- Sourceaccounts MAVELKI 20210.73%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
54 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
Alumni Lovanienses
Shared director
→
Aphea.Bio
Shared director
→
ASSOCIATIE KU Leuven
Shared director
→
Bedal International
Shared director
→
Show 50 more companies with a shared director
Biotalys
Shared director
→
Confo Therapeutics
Shared director
→
Festival van Vlaanderen Vlaams Brabant
Shared director
→
GEMMA FRISIUS-FONDS KU LEUVEN
Shared director
→
INNOVATION FUND
Shared director
→
JOOS
Shared director
→
Katholieke Hogeschool VIVES Noord
Shared director
→
Katholieke Hogeschool Vives Zuid
Shared director
→
Katholieke Universiteit te Leuven
Shared director
→
KBC ASSURANCES
Shared director
→
KBC Bank
Shared director
→
KBC Global Services
Shared director
→
KBC Groupe
Shared director
→
LUCA School of Arts
Shared director
→
MIJNEN
Shared director
→
MyCartis
Shared director
→
PRIVATE CAPITAL BELGIUM
Shared director
→
QUEST FOR GROWTH
Shared director
→
TELEVIC GROUP
Shared director
→
Thomas More Kempen
Shared director
→
THOR PARK
Shared director
→
UMICORE
Shared director
→
Vlaamse Interuniversitaire Raad
Shared director
→
VOKA - Kamer van Koophandel Vlaams-Brabant
Shared director
→
Z.org KU Leuven
Shared director
→
Airobot
Shared corporate director
→
ALRO HOLDINGS
Shared corporate director
→
BELGIAN CYCLING FACTORY
Shared corporate director
→
Blue Foot Membranes
Shared corporate director
→
Centrica Business Solutions Belgium
Shared corporate director
→
CORDA CAMPUS 2.0
Shared corporate director
→
Cubigo International
Shared corporate director
→
Down2Earth Capital
Shared corporate director
→
DRONEPORT
Shared corporate director
→
Eurofins Amatsigroup
Shared corporate director
→
FONTAINE HOLDINGS
Shared corporate director
→
Greenville
Shared corporate director
→
Kristalpark III
Shared corporate director
→
LIMBURG REGIONAL AIRPORT
Shared corporate director
→
MACHIELS BUILDING SOLUTIONS
Shared corporate director
→
Optiflux
Shared corporate director
→
PRIDIKTIV
Shared corporate director
→
PUNCH POWERTRAIN
Shared corporate director
→
QOMPIUM
Shared corporate director
→
TRENDMINER
Shared corporate director
→
UgenTec
Shared corporate director
→
ZONNECENTRALE BERINGEN
Shared corporate director
→
ZONNECENTRALE LIMBURG
Shared corporate director
→
ZONNECENTRALE LOMMEL
Shared corporate director
→
Capital and shareholders
Shareholders according to the acts
After 3 capital increases
act of 28-07-2017 ↗
- BVBA BEAGLE
- Stefan LOVERIX
- Philippe ALARD
- Philippe STAS
- Mark VAECK
- BVBA MAVELKI
- SA SICAR VESALIUS BIOCAPITAL I
- NV VESALIUS BIOCAPITAL ARKIV
- NV LIMBURGSE RECONVERSIE MAATSCHAPPIJ
- NV KMOFIN 2
- NV TRUSTCAPITAL
- COMM. VA VLAAMS INNOVATIEFONDS
- NV GEMMA FRISIUS-FONDS K.U. LEUVEN
- KATHOLIEKE UNIVERSITEIT LEUVEN
- NV BAEKELAND FONDS I
- NV GIMV
- NV ADVIESBEHEER GIMV HEALTH & CARE 2013
- NV BIOTECH FONDS VLAANDEREN
- FCPR BIODISCOVERY 4
After 3 capital increases
act of 20-08-2013 ↗
- Vlaams Innovatiefonds
- Katholieke Universiteit Leuven
The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 16-06-2022 Capital increase of 800,465.85 EUR · to 2,901,780.87 EUR · 2,229,709,902 new shares
- 16-06-2022 Capital reduction of 1,870,823.95 EUR · to 1,030,956.92 EUR · “aanzuivering van geleden verliezen”
- 30-04-2021 Capital increase of 1,681,494.29 EUR · to 3,750,901.18 EUR · 301,988,542 new shares
- 30-04-2021 Capital reduction of 1,649,586.16 EUR · to 2,101,315.02 EUR · “aanzuivering van geleden verliezen”
- 29-06-2020 Capital increase of 1,717,945.77 EUR · to 31,634,863.16 EUR · 308,535,057 new shares · in cash
- 29-06-2020 Capital reduction of 29,565,456.27 EUR · to 2,069,406.89 EUR · “aanzuivering van geleden verliezen”
- 14-08-2019 Capital increase of 295,701.62 EUR · to 29,916,917.39 EUR · 10,903,610 new shares · volledig afbetaald door overschrijvingen
- 17-07-2019 Capital increase of 1,400,000 EUR · to 29,621,215.77 EUR · 51,623,194 new shares · in cash
Show 11 older capital entries
- 28-07-2017 Capital increase of 404,063.40 EUR · 3,498,386 new shares · “conversie van obligaties”
- 28-07-2017 Capital increase of 4,504,755.73 EUR · 39,002,214 new shares · in kind
- 28-07-2017 Capital increase of 2,000,000 EUR · 17,316,018 new shares · in cash
- 10-04-2015 Capital increase of 2,839,907 EUR · 4,593,832 new shares · in cash
- 10-04-2015 Capital increase of 27 EUR · 7,162,772 new shares · “uitoefening van 27 Prijsaanpassingswarrants”
- 27-05-2014 Capital increase of 3,738,354 EUR · to 18,472,462.64 EUR · 6,047,160 new shares · “overschrijvingen op de bijzondere rekening geopend op naam van de vennootschap bij BNP Paribas Fortis NV”
- 20-08-2013 Capital increase of 2,211,791 EUR · 3,577,792 new shares
- 20-08-2013 Capital increase of 298,128 EUR · 482,251 new shares
- 20-08-2013 Capital increase of 2,974,189 EUR · 4,811,047 new shares
- 21-01-2011 Capital increase of 5,124,031.89 EUR · to 9,250,000.64 EUR · 8,288,631 new shares
- 21-06-2010 Capital increase of 1,875,968.75 EUR · to 4,125,968.75 EUR · 3,034,567 new shares
Public money · subsidies and aid
European research
2 projects · 374,599 EUR EU contributionProgrammes
Projects
Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs
European Training Network on Antiviral Drug Development
Similar companies · same sector, comparable size
AXETECS
BE 0797.888.742
Rebecq · Eq €124,093
SCouP
BE 0744.616.540
Jalhay · Eq €123,314
FADI
BE 0562.881.694
Gent · Eq €129,374
NB Please
BE 0700.420.271
Arlon · Eq €129,613
BULNES CONSULTING
BE 0713.473.305
Bertem · Eq €130,016
Of 1,177 companies in sector 72109 we hold annual accounts for 714. 465 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded01-07-2008
Fiscal year end31-12
Activities, NACEBEL 2025
72109Other research and development on natural sciences
Contact
E-mail
info@complix.com
E-invoicing
Reachable via Peppol
Peppol ID
0208:0898945025
Also
9925:BE0898945025
Registered
30-08-2023
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.